Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells.
暂无分享，去创建一个
[1] A. Khwaja,et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Begley,et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. , 1994, Bone marrow transplantation.
[3] H. Goldschmidt,et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.
[4] E. Shpall,et al. Release of tumor cells from bone marrow. , 1994, Blood.
[5] J. Craig,et al. Peripheral blood stem cell mobilization using high‐dose cyclophosphamide and G‐CSF in pretreated patients with lymphoma , 1993, British journal of haematology.
[6] M. Boccadoro,et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. , 1993, Bone marrow transplantation.
[7] P. Leblond,et al. Blood-derived stem cell collection in acute nonlymphoblastic leukemia: predictive factors for a good yield. , 1989, Experimental hematology.